secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001534969-26-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births
--------------------------------------------------------------------------------

- Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
- PRIME trial (5,018 women) showed PreTRM test cut early preterm births 56% (<32 wks) and 32% (<35 wks); NICU admissions down 20%.
- Cash and securities $86.8M; cash runway extended through 2029 via cost restructuring.
- Launched third physician partnership; active payer discussions with 13 payers across 15 states.
- CE marking submission for Europe on track for mid-2026; expanding European evidence base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000153496926000024/0001534969-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000153496926000024/sera-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001534969-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer